In our weekly Trends that Matter series, we provide engaging infographics from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's top pharma topic is biobetters. Developing biobetters is an emerging opportunity for pharmaceutical manufacturers.
A biobetter is a biological that has been structurally altered to improve upon an existing drug. Developing a biobetter is considered a lower risk for manufacturers than creating an entirely new drug. Many manufacturers are opting to invest in biobetters because biosimilar drugs have strict regulations and an in-depth FDA approval process.
Advantages of Developing Biobetters
Biobetters typically have lower costs for research and development and receive 12 years of market protection in the US. According to the Balance, “Biobetters are being developed using protein or glyco-engineering which, experts say, reduces the risk of immunogenicity, makes the drug safer and more effective, and requires lower dosing.”’
View the graph below, created by PRA Health Sciences, to see the relationship between investment risk and market adoption rate. This graph illustrates a greater potential for return with biobetters.
Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.